


**Product Name** : KPT-9274  
**Cat. No.** : PC-43212  
**CAS No.** : 1643913-93-2  
**Molecular Formula** : C<sub>35</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 610.625  
**Target** : p21-activated Kinase (PAK)  
**Solubility** : DMSO: ≥ 32 mg/mL



## Biological Activity

KPT-9274 (Padnarsertib) is a potent, specific, dual **NAMPT** and **PAK4** inhibitor with IC<sub>50</sub> of 120 nM (NAMPT), also is an orally bioavailable PAK4 allosteric modulator with IC<sub>50</sub> of 30 nM in MS-751 cell MTT assay.

KPT-9274 (Padnarsertib) attenuates the PAK4/β-catenin pathway, results in NAD depletion, and attenuates viability, invasion, and migration in several RCC cell lines (IC<sub>50</sub>=600 nM for Caki-1 cells).

KPT-9274 (Padnarsertib) attenuates G2/M transit and induces apoptosis, shows specificity for attenuation of NAD biosynthesis targets preferentially in RCC cells.

KPT-9274 (Padnarsertib) decreases tumor growth in xenograft model of RCC.

## References

Abu Aboud O, et al. *Mol Cancer Ther.* 2016 Sep;15(9):2119-29.

Aboukameel A, et al. *Mol Cancer Ther.* 2017 Jan;16(1):76-87.

Fulciniti M, et al. *Blood.* 2017 Apr 20;129(16):2233-2245.

Rane C, et al. *Sci Rep.* 2017 Feb 15;7:42555.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com